Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01124942
Other study ID # NA116/09
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 1, 2010
Est. completion date March 1, 2013

Study information

Verified date March 2022
Source Federico II University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Investigators will test the hypothesis that MGuard net protective stent, the investigational device, would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent percutaneous coronary interventions.


Description:

Embolization of thrombotic debris still represents a complication for ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary interventions (PCI). Distal embolization may decrease coronary and myocardial reperfusion after PCI in STEMI setting. Unfortunately, intracoronary filters present several important limitations limiting their use and their efficacy especially in presence of huge amount of thrombus. In this respect, recent trials investigated whether a default manual thrombectomy strategy before stenting would ameliorate angiographic as well as clinical outcomes for STEMI patients undergoing percutaneous revascularization. Of note, the most of embolization occurs when guidewire, and thrombectomy device cross the thrombus, and after the stent has been implanted as a consequence of plaque prolapse through the stent struts. MGuard net protective stent, the investigational device, is a bare-metal stent covered with a ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, that is anchored to the external surface of the struts. This biocompatible fiber net (string diameter 10-22 μm) has minimal effects on the stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net and isolating the prothrombotic intima components from the blood stream. This protocol will test the hypothesis that MGuard stent would be superior to conventional revascularization strategy (i.e. bare-metal stenting plus manual thrombectomy), for STEMI patients undergoing urgent PCI in terms of angiographic as well as clinical outcomes.


Recruitment information / eligibility

Status Completed
Enrollment 350
Est. completion date March 1, 2013
Est. primary completion date March 1, 2011
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - >/= 18-year-old patients, willing to participate the study, after informed consent signature - Female not pregnant or potentially child-bearing - > 1 mV ST segment elevation in two or more contiguous leads - Acute MI lasting more than 30 minutes and less than 12 hours - De novo acute MI - Infarct related artery reference vessel diameter >/= 2.5 mm - Patient suitable for stenting according to vessel and lesion features Exclusion Criteria: - Dual antiplatelet therapy contraindication - Ischemic stroke less than 30 days or previous haemorrhagic stroke - WBC count less than 1000 per mm3; - Platelet count less than 50.000 per mm3 - Life expectancy less than 1 year - Cardiogenic shock at admission - Previous stented infarct related artery - Stent thrombosis as the responsible for current STEMI - Inability to identify infarct related artery - True bifurcation lesion, or lesion near a side branch with a reference vessel diameter >/= 2.5 mm that could be diseased after stenting procedure - LBBB - Definitive pacing (or ECG abnormalities precluding ST-segment resolution evaluation - Participation other study

Study Design


Related Conditions & MeSH terms


Intervention

Device:
MGuard net protective coronary stent
It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 µm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
Bare-metal stent and manual thrombectomy device
Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent

Locations

Country Name City State
Italy Federico II University of Naples Naples

Sponsors (1)

Lead Sponsor Collaborator
Federico II University

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Piscione F, Danzi GB, Cassese S, Esposito G, Cirillo P, Galasso G, Rapacciuolo A, Leosco D, Briguori C, Varbella F, Tuccillo B, Chiariello M. Multicentre experience with MGuard net protective stent in ST-elevation myocardial infarction: safety, feasibility, and impact on myocardial reperfusion. Catheter Cardiovasc Interv. 2010 Apr 1;75(5):715-21. doi: 10.1002/ccd.22292. — View Citation

Rapacciuolo A, D'andrea C, Maresca G, di Pietro E, Piscione F, Chiariello M. Multiple MGuard stent implantation to treat massive right coronary artery dissection during primary coronary angioplasty. J Cardiovasc Med (Hagerstown). 2011 May;12(5):356-60. doi: 10.2459/JCM.0b013e328334092d. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients with Myocardial Perfusional Blush Grade 2-3 Myocardial Perfusional Blush Grade 2-3 at the end of the procedure 30 minutes after revascularization
Secondary Number of MACE Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure. 1 month
Secondary Complete ST-segment resolution Complete (>70%) ST-segment resolution at 60 minutes post-revascularization 60 minutes after revascularization
Secondary Thrombolysis in myocardial infarction antegrade coronary flow TIMI coronary flow at the end of the procedure 30 minutes after revascularization
Secondary Corrected TIMI Frame count Corrected TIMI Frame count at the end of the procedure 30 minutes after revascularization
Secondary Infarct related area reduction and left ventricular ejection fraction recovery Six-month infarct related area reduction and left ventricular ejection fraction recovery as compared with infarct related area and and left ventricular ejection fraction at admission. 6 months
Secondary Procedural device performance Device performance evaluated during the procedure in terms of pushability, trackability, crossability and deliverability 60 minutes after revascularizationl
Secondary Number of MACE Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure. 6 months
Secondary Number of MACE Number of Major Adverse Cardiovascular Events experienced among study population, including: cardiac death, myocardial infarction, target vessel failure. 12 months
See also
  Status Clinical Trial Phase
Completed NCT01864343 - Target Temperature Management In Myocardial Infarction - A Pilot Study N/A
Completed NCT00962416 - Comparison of Biomatrix Versus Gazelle in ST-Elevation Myocardial Infarction (STEMI) Phase 4
Active, not recruiting NCT00927615 - Comparison of Intracoronary Versus Intravenous Abciximab in ST-segment Elevation Myocardial Infarction (CICERO) N/A
Completed NCT03135275 - MULTivessel Immediate Versus STAged RevaScularization in Acute Myocardial Infarction -The MULTISTARS AMI Trial N/A
Recruiting NCT02592694 - Intracoronary Cocktail Injection Combined With Thrombus Aspiration in STEMI Patients Treated With Primary Angioplasty Phase 4
Withdrawn NCT01991366 - Should Integrilin be an Integral Part of Adjunctive Therapy in Patients Undergoing Primary PCI for ST-Elevation MI?
Completed NCT02158468 - Effect of Conditioning on Myocardial Damage in STEMI N/A
Completed NCT01197729 - OPTAMI (Optimized Therapy of Acute Myocardial Infarction) - Registry N/A
Completed NCT06426537 - Colchicine's Efficacy in MI Patients: Comparing PCI and Non-Reperfusion Approaches Early Phase 1
Completed NCT01882179 - Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size Phase 3
Terminated NCT00719914 - A Safety/Efficacy Study of Intracoronary Integrilin to Improve Balloon Angioplasty Outcomes for the Treatment of Heart Attacks Phase 2
Completed NCT00952224 - Myocardial Salvage Assessed by Cardiovascular Magnetic Resonance - Impact on Outcome N/A
Completed NCT00378391 - European Registry on STEMI Patients Transferred for PCI With Upstream Use of Abciximab - EuroTransfer Registry N/A
Withdrawn NCT04303377 - Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction Phase 2
Completed NCT03523624 - Factor XIII and Other Biomarkers in ST Segment Elevation Myocardial Infarction
Completed NCT01531114 - PraSugrel vs TicagrElor in ST-Elevation Myocardial Infarction paTients With Diabetes Mellitus Phase 3
Active, not recruiting NCT01960933 - Primary PCI in Patients With ST-elevation Myocardial Infarction and Multivessel Disease: Treatment of Culprit Lesion Only or Complete Revascularization N/A
Completed NCT00502528 - Endothelin Receptor Blockade in Acute ST-elevation Myocardial Infarction Phase 2
Recruiting NCT02062554 - Brasilia Heart Study
Recruiting NCT04150016 - In-stent Repair and Vessel Reaction of STEMI Patients With OCT N/A